The present study showed that dose-dense chemotherapy significantly improved the pCR rate of LNs in patients with HER2-positive breast cancer who received trastuzumab; however, it did not achieve significant improvement in the pCR rate of breast tumors. This evidence concerns the gene ERBB2 and breast carcinoma.